|
|
Volumn 31, Issue 1, 1994, Pages 83-94
|
|
Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
|
|
Author keywords
antiestrogens; breast cancer; clinical trial; droloxifene
|
|
Indexed keywords
ANTIESTROGEN;
DROLOXIFENE;
ESTROGEN RECEPTOR;
FOLLITROPIN;
LUTEINIZING HORMONE;
SEX HORMONE BINDING GLOBULIN;
TAMOXIFEN;
ADULT;
AGED;
ARTICLE;
BREAST METASTASIS;
CARCINOGENESIS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG TOLERANCE;
FEMALE;
HEART FAILURE;
HOT FLUSH;
HUMAN;
HYPERCALCEMIA;
INOPERABLE CANCER;
LUNG EMBOLISM;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
NAUSEA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
RECEPTOR AFFINITY;
RECURRENT CANCER;
THROMBOCYTOPENIA;
THROMBOPHLEBITIS;
VOMITING;
BREAST NEOPLASMS;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ESTROGEN ANTAGONISTS;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
MIDDLE AGED;
NEOPLASM METASTASIS;
NEOPLASM STAGING;
POSTMENOPAUSE;
PROGNOSIS;
TAMOXIFEN;
TIME FACTORS;
|
|
EID: 0028068906
PISSN: 01676806
EISSN: 15737217
Source Type: Journal
DOI: 10.1007/BF00689679 Document Type: Article |
|
Times cited : (79)
|
|
References (30)
|
